IQVIA (NYSE:IQV – Get Free Report) had its price target lifted by Morgan Stanley from $245.00 to $250.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an “overweight” ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on innovative drug delivery technologies, ...

The semiconductor industry is at the heart of the tech boom, serving as the backbone for innovations in computing, ...

Stratos Wealth Partners LTD. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 5.3% during the ...

Q4 2024 Earnings Call Transcript February 6, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $3.12, ...

IQVIA Holdings Inc (IQV) reports robust financial performance with record free cash flow and strategic partnership renewals, ...

AI-related partnerships on the rise, particularly in the health technology space. In January, NVIDIA struck alliances with ...

Q4 2024. Management View. CEO Ari Bousbib highlighted that IQVIA achieved solid revenue growth of 5.5% at constant currency ...

IQVIA reaffirms its 2025 outlook, projecting up to $16.13 billion in revenue and EPS of $11.70-$12.10. Strong TAS growth and solid R&DS bookings fuel confidence.

Contract research firm IQVIA Holdings beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare data and analytics services.